Top 100 AI · United States
Daphne Koller
insitro 
- Score
- 7,2070 today
- Rank
- 74/198 =
- over 90 days
- ——
Daphne Koller is 74th in the Favikon Index Top 100 AI, with a Favikon score of 7,667 points. Koller has 48.1K followers across platforms.
Data as of Oct 25, 2026.
The raw numbers · last 90 days
- Median views
- 106.3K
- per post
- Median engagements
- 1.3K
- per post
- Posts
- 12
- over 90 days
- Followers
- 48.1K
- all scored platforms
What drives the score
Percentiles 0–100 against all tracked creators.
- Reach · 30%93
Average views per post over 90 days
- Engagement · 30%84
Average reactions per post
- Audience · 30%55
Total followers, relative to population
- Consistency · 10%69
Posting frequency (25 posts / 90 days = 100)
Platforms
48.1K total followers
| Platform | Followers | Score |
|---|---|---|
| LinkedIn@daphne-koller-4053a820 | 48.1K | 9,539t1 |
Last 30 days
Koller's top posts
- LinkedIn · 9 days ago#1
This week insitro announced a collaboration with AstraZeneca to discover new medicines for MASH and cardiomyopathies. Here is why I am excited about it. Start with the science. MASH and cardiomyopathy are both single …
DK230.3K views3K engagements
- LinkedIn · 4 days ago#2
Forbes named me one of its 250 Greatest Living American Optimists this week, which prompted a useful question: what, exactly, am I optimistic about? Quite a lot. I’m optimistic about science because our ability to obs…
DK123.3K views1.6K engagements
- LinkedIn · 18 days ago#3
Predictive biology is having quite a moment. Biohub, U.S. Department of Energy (DOE), The National Institutes of Health, Google DeepMind, Isomorphic Labs, and Meta are putting $1.8 billion into an open, large-scale ma…
DK92.2K views1.2K engagements
LinkedIn · 11 days ago#4DKToday, insitro announced a strategic collaboration with AstraZeneca for the AI-enabled discovery of novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. insitro will rec…
61.4K views819 engagements
Head-to-head
